83% of Refractory Patients Achieve Long-Term Remission: IASO Bio Announces Publication of CAR-T Therapy for Multiple Sclerosis in Cell

On October 16, IASO Bio announced in an international academic journalCellPublished online its independently developedFully Human BCMA-Targeted CAR-T Cell Therapy Ixcellen Injection for Progressive Multiple Sclerosis (PMS)The research results.

Eque-cel (Idecabtagene Vicleucel) Injection is a CAR-T cell therapy targeting B-cell maturation antigen (BCMA). It transfects autologous T cells using a lentivirus as the gene carrier. The CAR comprises a fully human scFv, CD8a hinge and transmembrane domain, 4-1BB co-stimulatory molecule, and CD3ζ activation domain. Based on rigorous molecular structure screening and comprehensive in vivo and in vitro functional evaluation, Eque-cel Injection demonstrates rapid and potent efficacy, with remarkable persistence in vivo, enabling patients to achieve deep and sustained remission.

Published inCellThe article title is "Anti-BCMA CAR-T Cells in Progressive Multiple Sclerosis (Targeted BCMA CAR-T Cell Therapy for Progressive Multiple Sclerosis)". This research is based on an investigator-initiated clinical study (NCT04561557) led by Professor Wei Wang's team from the Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.

This study enrolled five patients with progressive multiple sclerosis (PMS), including one patient with primary progressive MS (PPMS) and four patients with secondary progressive MS (SPMS). The average age of onset was 38.2 years, and the baseline mean EDSS score was 6.2. After all patients received a single infusion of Ixcell injection, the following observations were made:

Significant efficacy:All patients showed significant improvements in EDSS scores, 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW); cerebrospinal fluid oligoclonal bands (OCBs) completely disappeared, and Kappa free light chain (κFLC) levels significantly decreased; moreover, MRI follow-up revealed no new or enlarging gadolinium-enhanced T1 lesions or T2 hyperintense lesions.

Good Safety:80% of patients only experienced transient Grade 1 cytokine release syndrome (CRS), with no ≥Grade 2 CRS; no immune effector cell-associated neurotoxicity syndrome (ICANS) or other neurotoxicity reactions were observed.

Professor Wang Wei from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, stated that he is very pleased the team's research findings have been published inCell, this is an important step we have taken in the field of cell therapy. They are the first to apply CAR-T therapy targeting B lymphocytes to multiple sclerosis and other refractory neuroimmunological diseases, demonstrating the safety and efficacy of this therapy in patients with progressive multiple sclerosis. Encouragingly,83% of refractory patients achieved long-term clinical remission without drug maintenance after receiving treatment.This study not only overturns the existing treatment paradigm but also reveals a novel regulatory mechanism of the immune microenvironment in the central nervous system, paving a new direction for the immunotherapy of chronic neuroinflammatory diseases. Based on the significant efficacy of Equecabtagene Autoleucel (Inebilizumab) in depleting plasma cells and B cells, researchers are actively advancing the application of this therapy in more autoimmune diseases, including neuromyelitis optica spectrum disorders and myasthenia gravis, with encouraging clinical outcomes observed so far. It is anticipated that this CAR-T therapy will offer a new treatment option for more patients with autoimmune diseases.

References:
[1] International top journal "Cell" publishes the research results of IASO Bio's BCMA CAR-T Equecabtagene Autoleucel Injection in treating the autoimmune disease multiple sclerosis. From https://www.prnasia.com/story/507474-1.shtml

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does WuXi AppTec support or oppose the views mentioned in the article. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.